Lactococcus lactis As a Versatile Vehicle for Tolerogenic Immunotherapy

Cook, Dana Paulina; Gysemans, Conny; Mathieu, Chantal

doi:10.3389/fimmu.2017.01961

Cited by 42 publications

(39 citation statements)

References 132 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition to approaches for systemic delivery, antigens may be delivered to mucosal tissues by genetically modified Lactobacillus lactis bacteria to achieve oral tolerance. This platform for delivery of bioactive proteins is dependent on an external thymidine to survive, ensuring that the modified bacteria strain cannot survive outside of the human body [22]. L. lactis-based secretion of diseasedriving gluten T cell epitopes has been tested in a mouse model for CeD [23].…”

Section: Box 4 Regulatory T Cells In General and In Celiac Diseasementioning

confidence: 99%

Therapeutic and Diagnostic Implications of T Cell Scarring in Celiac Disease and Beyond

Christophersen

Risnes

Dahal‐Koirala

et al. 2019

Trends in Molecular Medicine

View full text Add to dashboard Cite

Few therapeutic and diagnostic tools specifically aim at T cells in autoimmune disorders, but are T cells a narrow target in these diseases? Lessons may be learned from celiac disease (CeD), one of the few autoimmune disorders where the T cell driving antigens are known, i.e. dietary gluten proteins. T cell clonotypes specific to gluten are expanded, persist for decades and express a distinct phenotype in CeD patients. Cells with this phenotype are increased also in other autoimmune conditions. Accordingly, disease-specific CD4 + T cells form an immunological scar in CeD and probably other autoimmune disorders. We discuss approaches how such T cells may be targeted for better treatment and diagnosis via their antigen specificity or via their expression of characteristic phenotypic markers.

show abstract

Section: Box 4 Regulatory T Cells In General and In Celiac Diseasementioning

confidence: 99%

Therapeutic and Diagnostic Implications of T Cell Scarring in Celiac Disease and Beyond

Christophersen

Risnes

Dahal‐Koirala

et al. 2019

Trends in Molecular Medicine

View full text Add to dashboard Cite

show abstract

“…To overcome this problem, several different techniques have been used with promising results, at least in animal studies. The Lactococcus lactis bacteria has been used as a vehicle for different autoantigens [102][103][104], and autoimmune diabetes has been reversed in NOD mice [105]. Other vehicles used include attenuated salmonella [106] and vaccinia virus [107,108].…”

Section: Different Routes For Administration Of Autoantigenmentioning

confidence: 99%

Autoantigen Treatment in Type 1 Diabetes: Unsolved Questions on How to Select Autoantigen and Administration Route

Ludvigsson¹

2020

IJMS

View full text Add to dashboard Cite

Autoantigen treatment has been tried for the prevention of type 1 diabetes (T1D) and to preserve residual beta-cell function in patients with a recent onset of the disease. In experimental animal models, efficacy was good, but was insufficient in human subjects. Besides the possible minor efficacy of peroral insulin in high-risk individuals to prevent T1D, autoantigen prevention trials have failed. Other studies on autoantigen prevention and intervention at diagnosis are ongoing. One problem is to select autoantigen/s; others are dose and route. Oral administration may be improved by using different vehicles. Proinsulin peptide therapy in patients with T1D has shown possible minor efficacy. In patients with newly diagnosed T1D, subcutaneous injection of glutamic acid decarboxylase (GAD) bound to alum hydroxide (GAD-alum) can likely preserve beta-cell function, but the therapeutic effect needs to be improved. Intra-lymphatic administration may be a better alternative than subcutaneous administration, and combination therapy might improve efficacy. This review elucidates some actual problems of autoantigen therapy in the prevention and/or early intervention of type 1 diabetes.

show abstract

“…Therapeutic delivery for the oral or mucosal is mediated by using LAB as a vector, which is more advantageous because they are inherently nonpathogenic and able to survive in the harsh gastric environment. LAB is used in the treatment of idiopathic gastrointestinal disorders that have fewer treatment options . Acute infection response, as well as chronic low‐grade inflammation, will starts from the mucosal layer as mucosal administration is the best mode of administration.…”

Section: Synthetic Biology For the Study Of Host–microbe Interactionsmentioning

confidence: 99%

Efficient engineered probiotics using synthetic biology approaches: A review

Yadav

Shukla

2019

Biotech and App Biochem

View full text Add to dashboard Cite

The uses of probiotics‐based food supplements are getting emphasis due to their power to ensure better health conditions. Probiotics have diverse and significant applications in the health sector, so probiotic strains require an understanding of the genome level organizations. Probiotics elucidate various functional parameters that control their metabolic functions. In this review, we have compiled aspects of synthetic biology, which are used for the optimization of metabolic processes in probiotics for their use as a supplement in allopathic medicines. Synthetic biology approaches provide information about diverse biosynthetic pathways and also facilitate the novel metabolic engineering approaches for probiotics strain improvement. We have discussed the synthetic biology approaches for producing engineered probiotics via genetic circuits, expression systems, and genome editing tools like CRISPR–Cas and PEVLAB. This review also enlightens future challenges in the development of engineered probiotics.

show abstract

Lactococcus lactis As a Versatile Vehicle for Tolerogenic Immunotherapy

Cited by 42 publications

References 132 publications

Therapeutic and Diagnostic Implications of T Cell Scarring in Celiac Disease and Beyond

Therapeutic and Diagnostic Implications of T Cell Scarring in Celiac Disease and Beyond

Autoantigen Treatment in Type 1 Diabetes: Unsolved Questions on How to Select Autoantigen and Administration Route

Efficient engineered probiotics using synthetic biology approaches: A review

Contact Info

Product

Resources

About